This reduction in tumor weight and volume coincided with a decrease in expression of Ki-67 and phosphorylated-S6, as well as an increase in cleaved caspase 3 and phosphorylated-AKT, suggesting that everolimus increased AKT activity in in vivo models [25]. Here, MKI67 is linked to neoplasm.